Overview
Co-Management of Severe Asthma: Improving Processes for Primary Care Assessment and Referral to Specialty Care
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Can you recognize severe asthma? Access these educational resources and tools to help you enhance assessment and diagnostic practices and introduce guideline-recommended referral processes. Then share this invaluable educational content with your team by using the downloadable slide decks and discussion guides to initiate meaningful conversations and improve interprofessional care. And to assist providers with optimizing their EMR workflows, this activity also provides you with practical guidance for integrating clinical tools, algorithms, patient educational materials, and alerts within your system. Drive changes to positively impact care for your patients with asthma by diagnosing severe asthma earlier and reducing delays in referring to a specialist.
This program is intended for primary care providers managing patients with severe asthma.
Asthma is a chronic inflammatory disease of the airway with increasing prevalence. Approximately 5-10% of patients with asthma can be classified as having severe asthma in which they continue to experience symptoms despite therapy. Guidelines recommend referral to a specialist so that patients with uncontrolled severe asthma can receive add-on therapies and reduce exposure to side effects associated with chronic use of oral corticosteroids. Yet, evidence indicates that referral rates by primary care providers are suboptimal and that specialty care for asthma is underutilized. Primary care providers must be able to recognize severe asthma, tease out potential causes, and refer in a timely manner for patients with severe asthma to realize benefits.
• Review guideline recommendations around situations where referral of adult patients with asthma are warranted
• Introduce protocols to recognize and facilitate timely referral of high-risk patients with asthma to specialty care
• Outline coordination of care practices to improve patient-centric management of severe asthma
• Introduce protocols to recognize and facilitate timely referral of high-risk patients with asthma to specialty care
• Outline coordination of care practices to improve patient-centric management of severe asthma
Provided by Penn State College of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from AstraZeneca Pharmaceuticals.
Njira Lugogo, MD
Professor of Medicine
Department of Medicine, Division of Pulmonary, Critical Care Medicine
University of Michigan
Ann Arbor, MI
Professor of Medicine
Department of Medicine, Division of Pulmonary, Critical Care Medicine
University of Michigan
Ann Arbor, MI
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Jenkintown, PA
Penn State College of Medicine and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Njira Lugogo, MD
Advisory Board/Consultant: AstraZeneca, Genentech, GSK, Sanofi/Regeneron, Teva
Speaker: AstraZeneca, GSK
Neil Skolnik, MD
Advisory Board/Consultant: Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Genentech,
GSK, Idorsia, Lilly, Novo Nordisk, Sanofi, Sanofi Pasteur
Research Support: AstraZeneca, Bayer, GSK, Novo Nordisk, Sanofi, Sanofi Pasteur
Speaker: Astellas, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, GSK, Heartland, Lilly, Novo Nordisk, Sanofi Pasteur, Teva
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Penn State College of Medicine and ACHL staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Penn State College of Medicine and ACHL require the speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6994-24-T.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
